Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.

Pregnant patients with vs without connective tissue diseases faced increased risks for adverse maternal and fetal outcomes, including maternal death, preterm labor, and hypertensive disorders.

Anti-inflammatory medications are a cornerstone of treatment for mixed connective tissue disease (MCTD) but your diet also is important. Eating foods that suppress inflammation may help prevent ...

Background: Connective tissue disorders (CTDs) are a heterogeneous group of ... myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), SH, gastroesophageal reflux disease (GERD), hypothyroidism, ...

Wearable devices are associated with a reduced risk for major adverse cardiovascular events and all-cause mortality in patients with ischemic heart disease. However, evidence of their effects on ...

To address these challenges, we propose a mixed CNN-transformer network for Mars HSI classification with graph contrastive learning to enhance classification performance. Specifically, we introduce an ...

Patients with connective tissue diseases who experienced ... (1.8%), primary Sjögren syndrome (1.1%), and mixed connective tissue disease (MCTD; 0.04%). Patients with MCTDs were excluded from ...

The American Cancer Society's estimates for soft tissue sarcomas in the United States for 2025 are: About 13,520 new soft tissue sarcomas will be diagnosed (7,600 in males and 5920 in females). About ...